In:
The American Journal of Tropical Medicine and Hygiene, American Society of Tropical Medicine and Hygiene, Vol. 106, No. 4 ( 2022-04-06), p. 1104-1107
Abstract:
Severe cases of COVID-19 are being reported in patients with comorbidities and drug-induced immunosuppression. The risk seems to depend on the type of immunosuppressive agents used, and it is particularly high with rituximab because of its long-lasting effects. We report a 71-year-old man with COVID-19, mantle cell lymphoma, and rituximab-associated immunodeficiency. His COVID-19 clinical course was severe, unremitting, prolonged, and with frequent acute exacerbations requiring hospitalization. Viral shedding and failure to develop anti-severe acute respiratory syndrome coronavirus 2 antibodies continued for at least 6 months.
Type of Medium:
Online Resource
ISSN:
0002-9637
,
1476-1645
DOI:
10.4269/ajtmh.21-1010
Language:
Unknown
Publisher:
American Society of Tropical Medicine and Hygiene
Publication Date:
2022
detail.hit.zdb_id:
1491674-5
Bookmarklink